Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

Journal of Clinical Investigation

Volumn 126, Issue 2, 2016, Pages 605-610

  DiLillo, David J ^a   Palese, Peter ^b   Wilson, Patrick C ^c   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EPITOPE; FC RECEPTOR; HEMAGGLUTININ; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1A01; MONOCLONAL ANTIBODY 1A05; MONOCLONAL ANTIBODY 1F02; MONOCLONAL ANTIBODY 1F05; MONOCLONAL ANTIBODY 2B06; MONOCLONAL ANTIBODY 2G02; MONOCLONAL ANTIBODY 3C02; MONOCLONAL ANTIBODY 4C04; MONOCLONAL ANTIBODY 4G01; MONOCLONAL ANTIBODY 4G05; MONOCLONAL ANTIBODY 6F12; MONOCLONAL ANTIBODY 7B2; MONOCLONAL ANTIBODY F16; MONOCLONAL ANTIBODY PY102; NEUTRALIZING ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CELL POPULATION; CONTROLLED STUDY; DRUG POTENCY; EFFECTOR CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SURVIVAL; SURVIVAL RATE; WEIGHT REDUCTION; ANIMAL; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; KNOCKOUT MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; INFLUENZA A VIRUS; MICE; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, FC;

EID: 84956934982     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI84428     Document Type: Review

References (15)

1. WHO. Influenza (Seasonal) Fact sheet 211. WHO Web site. http://www.who.int/mediacentre/factsheets/fs211/en/. Updated March 1, 2014. Accessed November 30, 2015.
2. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189-202.
3. Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses. 2014;6(6):2465-2494.
4. Wang TT, Palese P. Biochemistry. Catching a moving target. Science. 2011;333(6044):834-835.
5. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167-182.
6. Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212(9):1361-1369.
7. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143-151.
8. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-856.
9. Pincetic A, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707-716.
10. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510-1512.
11. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 1994;76(3):519-529.
12. Dahan R et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295.
13. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012;109(16):6181-6186.
14. El Bakkouri K, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022-1031.
15. Corti D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120(5):1663-1673.